38514804|t|The Alzheimer's disease risk gene BIN1 regulates activity-dependent gene expression in human-induced glutamatergic neurons.
38514804|a|Bridging Integrator 1 (BIN1) is the second most important Alzheimer's disease (AD) risk gene, but its physiological roles in neurons and its contribution to brain pathology remain largely elusive. In this work, we show that BIN1 plays a critical role in the regulation of calcium homeostasis, electrical activity, and gene expression of glutamatergic neurons. Using single-cell RNA-sequencing on cerebral organoids generated from isogenic BIN1 wild type (WT), heterozygous (HET) and homozygous knockout (KO) human-induced pluripotent stem cells (hiPSCs), we show that BIN1 is mainly expressed by oligodendrocytes and glutamatergic neurons, like in the human brain. Both BIN1 HET and KO cerebral organoids show specific transcriptional alterations, mainly associated with ion transport and synapses in glutamatergic neurons. We then demonstrate that BIN1 cell-autonomously regulates gene expression in glutamatergic neurons by using a novel protocol to generate pure culture of hiPSC-derived induced neurons (hiNs). Using this system, we also show that BIN1 plays a key role in the regulation of neuronal calcium transients and electrical activity via its interaction with the L-type voltage-gated calcium channel Cav1.2. BIN1 KO hiNs show reduced activity-dependent internalization and higher Cav1.2 expression compared to WT hiNs. Pharmacological blocking of this channel with clinically relevant doses of nifedipine, a calcium channel blocker, partly rescues electrical and gene expression alterations in BIN1 KO glutamatergic neurons. Further, we show that transcriptional alterations in BIN1 KO hiNs that affect biological processes related to calcium homeostasis are also present in glutamatergic neurons of the human brain at late stages of AD pathology. Together, these findings suggest that BIN1-dependent alterations in neuronal properties could contribute to AD pathophysiology and that treatment with low doses of clinically approved calcium blockers should be considered as an option to slow disease-onset and progression.
38514804	4	23	Alzheimer's disease	Disease	MESH:D000544
38514804	34	38	BIN1	Gene	274
38514804	87	92	human	Species	9606
38514804	124	145	Bridging Integrator 1	Gene	274
38514804	147	151	BIN1	Gene	274
38514804	182	201	Alzheimer's disease	Disease	MESH:D000544
38514804	203	205	AD	Disease	MESH:D000544
38514804	348	352	BIN1	Gene	274
38514804	396	403	calcium	Chemical	MESH:D002118
38514804	563	567	BIN1	Gene	274
38514804	632	637	human	Species	9606
38514804	692	696	BIN1	Gene	274
38514804	776	781	human	Species	9606
38514804	794	798	BIN1	Gene	274
38514804	973	977	BIN1	Gene	274
38514804	1176	1180	BIN1	Gene	274
38514804	1228	1235	calcium	Chemical	MESH:D002118
38514804	1337	1343	Cav1.2	Gene	775
38514804	1345	1349	BIN1	Gene	274
38514804	1417	1423	Cav1.2	Gene	775
38514804	1531	1541	nifedipine	Chemical	MESH:D009543
38514804	1545	1552	calcium	Chemical	MESH:D002118
38514804	1631	1635	BIN1	Gene	274
38514804	1715	1719	BIN1	Gene	274
38514804	1772	1779	calcium	Chemical	MESH:D002118
38514804	1841	1846	human	Species	9606
38514804	1871	1873	AD	Disease	MESH:D000544
38514804	1923	1927	BIN1	Gene	274
38514804	1993	1995	AD	Disease	MESH:D000544
38514804	2069	2085	calcium blockers	Chemical	-
38514804	Negative_Correlation	MESH:D002118	MESH:D009543
38514804	Association	274	775
38514804	Association	MESH:D009543	274
38514804	Association	MESH:D002118	775
38514804	Association	MESH:D000544	274
38514804	Association	MESH:D002118	274

